Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF – Get Free Report)’s stock price shot up 9.7% during mid-day trading on Monday . The company traded as high as $14.70 and last traded at $14.70. 300 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 4,451 shares. The stock had previously closed at $13.40.
Ono Pharmaceutical Price Performance
The company has a market capitalization of $7.56 billion, a P/E ratio of 7.99 and a beta of 0.54. The firm has a fifty day simple moving average of $13.85 and a 200-day simple moving average of $15.13.
Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported $0.34 earnings per share (EPS) for the quarter. The business had revenue of $754.85 million during the quarter. Ono Pharmaceutical had a return on equity of 14.95% and a net margin of 24.26%. On average, sell-side analysts predict that Ono Pharmaceutical Co., Ltd. will post 1.44 earnings per share for the current fiscal year.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.
Featured Articles
- Five stocks we like better than Ono Pharmaceutical
- Quiet Period Expirations Explained
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- The 3 Best Fintech Stocks to Buy Now
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- The Most Important Warren Buffett Stock for Investors: His Own
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.